hairlossYes, hair loss can happen on semaglutide (the medicine in Ozempic and Wegovy) and on tirzepatide (Mounjaro and Zepbound), but for most people it is a temporary shedding called telogen effluvium, linked to fast weight loss rather than permanent balding. It usually shows up a few months after the weight starts coming off and settles once weight and eating stabilize. Here is what the trials, the newest research and dermatology guidance actually say.
Key points
- In the FDA-reviewed trials, hair loss was reported in 3% of adults on semaglutide 2.4 mg versus 1% on placebo, and in 4-5% on tirzepatide versus 1% on placebo.
- Women reported it far more often than men in the tirzepatide trials (7.1% vs 0.5%).
- The usual pattern is telogen effluvium: diffuse shedding that tends to start about 2-3 months after a trigger such as rapid weight loss.
- A large 2026 real-world study linked GLP-1 medicines to higher odds of both telogen effluvium and pattern hair loss, but it cannot prove cause and effect.
- Do not stop a prescribed medicine on your own. Talk to your prescriber and, if shedding is heavy or patchy, a dermatologist.
What the clinical trials found
GLP-1 receptor agonists such as semaglutide, and the dual GIP/GLP-1 agonist tirzepatide, were developed for type 2 diabetes and are now also approved for chronic weight management. Their official prescribing information lists hair loss among the side effects seen in the weight-loss trials.
| Medicine (weight-loss trials) | Hair loss on medicine | Hair loss on placebo |
|---|---|---|
| Semaglutide 2.4 mg, adults | 3% | 1% |
| Semaglutide 2.4 mg, ages 12 and up | 4% | 0% |
| Tirzepatide 5, 10 and 15 mg, adults | 4-5% | 1% |
| Tirzepatide, women vs men (all doses) | 7.1% vs 0.5% | 1.3% vs 0% |
Figures come from the FDA-approved semaglutide 2.4 mg label and the tirzepatide (weight management) label. Two things stand out. First, the absolute numbers are small: most people in these trials did not report hair loss. Second, the tirzepatide label itself ties the hair loss to weight reduction, and the gap between women and men is large.
Why weight-loss medicines can trigger shedding
Every hair follicle cycles through a growing phase (anagen), a short transition (catagen) and a resting phase (telogen). Normally only about 10% of follicles are resting at any time. A significant shock to the body can push many follicles into the resting phase at once; a few months later, those hairs fall out together. That is telogen effluvium.
According to Cleveland Clinic, known triggers include high fever, childbirth, surgery, severe illness, thyroid problems, certain medicines, psychological stress, and crash or restrictive diets that lack enough protein. Rapid weight loss is on that list. GLP-1 medicines reduce appetite strongly, so many people eat far less, and sometimes less protein, than before. That combination is a plausible explanation for much of the shedding.
Whether the drugs themselves add anything beyond the weight loss is still an open question. Researchers have floated ideas such as nutritional shortfalls and hormonal shifts, but these have not been proven.
What newer research adds
A real-world study published in JAAD International in February 2026 (Vidal and colleagues) used the TriNetX health-records network to compare GLP-1 users with matched people not taking these drugs. It included nearly 550,000 patients. At 12 months, GLP-1 users had higher odds of telogen effluvium (adjusted odds ratio about 1.76), androgenetic alopecia (about 1.64) and non-scarring hair loss overall (about 1.40), even after adjusting for age, sex, BMI and diabetes (summary; George Washington University release).
What it did not show: it is observational, based on diagnosis codes, so it cannot prove the medicines caused the hair loss. People starting these drugs may also see doctors more often, which makes a diagnosis more likely to be recorded. The link with pattern hair loss is interesting, but it may simply reflect shedding that unmasked thinning that was already developing.
A smaller claims-database study posted as a preprint (not confirmed as peer reviewed) compared about 1,900 semaglutide users with about 1,300 people taking a different weight-loss medicine. The overall result was not statistically significant, though women on semaglutide had a higher rate of hair-loss diagnoses (medRxiv). The authors called their findings inconclusive.
What GLP-1 shedding usually looks like
- Timing: shedding typically begins about 2-3 months after a trigger, so it often appears a few months into treatment or after a big drop in weight.
- Pattern: diffuse thinning all over, often most noticeable on top of the scalp or as more hair in the brush and shower drain. No bald patches.
- Amount: healthy people shed roughly 50-150 hairs a day; during telogen effluvium it can rise to around 300.
- Scalp: no pain, redness or scaling.
- Course: acute telogen effluvium lasts under six months and most cases resolve; visible regrowth often takes 6-12 months after the trigger settles.
If what you see does not fit this picture, for example a receding hairline or a thinning crown that keeps progressing, it may be pattern hair loss. Our Norwood scale guide and receding hairline guide explain how that looks.
What you can do
Talk to your prescriber first
Do not stop or change the dose on your own. Your prescriber can review how fast you are losing weight and whether the plan needs adjusting. Shedding from telogen effluvium generally settles once the trigger eases, even if treatment continues.
Protect your nutrition
Because appetite drops so sharply, it is easy to undereat protein, iron and calories. Ask your doctor or a registered dietitian about protein targets and a balanced eating plan. Supplements only help when you are actually low in something; a 2026 Cleveland Clinic Journal of Medicine review notes the benefit of supplements in people without a deficiency is uncertain, and too much vitamin A can itself cause shedding.
Ask about blood tests
For persistent shedding, dermatologists commonly check a complete blood count, metabolic panel, thyroid function (TSH) and ferritin, adding others based on your history. Low iron or an underactive thyroid can cause or prolong shedding and are treatable.
Be gentle with your hair
Avoid tight styles, harsh chemical treatments and high heat while the shedding settles. Our hair care tips cover the basics.
Medical treatment, if needed
For acute telogen effluvium, reassurance and time are often enough; minoxidil is not routinely recommended for that alone. If testing shows underlying androgenetic alopecia, a dermatologist may discuss options such as topical minoxidil, or prescription medicines such as finasteride (men) or spironolactone (some women), each with its own side effects and monitoring. A hair transplant is not a treatment for temporary shedding; it is only considered for stable pattern loss (see our FUE guide).
When to see a doctor or dermatologist
- Shedding that lasts longer than about six months
- Bald patches, broken hairs, or loss of eyebrows or eyelashes
- Scalp pain, burning, itching, redness or scaling
- Hair loss with fatigue, feeling cold, weight changes you can't explain, or heavy periods
- Any shedding that is causing you real distress
FAQ
Does Ozempic hair loss grow back?
In most cases, yes. Telogen effluvium does not destroy follicles, and hair usually regrows over 6-12 months once weight and nutrition stabilize. If you also have pattern hair loss, that part will not reverse without treatment.
Is hair loss more common on tirzepatide than semaglutide?
The labels report 4-5% for tirzepatide and 3% for semaglutide 2.4 mg, but these came from different trials with different people and amounts of weight loss, so they cannot be compared head to head.
Should I stop my GLP-1 medicine if my hair is shedding?
Not without talking to your prescriber. The shedding is usually temporary, while the medicine may be treating important health conditions. Your doctor can weigh the options with you.
Have a question about your own shedding? Ask our hair loss team, browse the hair loss FAQ, or read more in Hairloss Labs.